



IFU

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. Serial No.: 10/576,061

Inventors: Alain D. BARON, et al

Filed: April 17, 2006

Title: SILYL PHENOLS FOR PROMOTING  
VASCULAR HEALTH

Confirmation No.: 6693

TC/A.U.: TBD

Examiner: TBD

Docket No. 0302-UTL2-0

TRANSMITTAL

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The following documents are enclosed herewith for your review and consideration:

Document	No. of Pages
Information Disclosure Statement	2
PTO/SB/08 Forms	5
40 References	
Return Receipt Postcard	
<b>Total No. of Pages Transmitted (including this sheet):</b>	<b>8</b>

CERTIFICATE OF MAILING  
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage in an envelope addressed to the Commissioner for Patents, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, DC 20231

9/18/06  
Date of Deposit

Name of Person Mailing Paper  
Signature of Person Mailing Paper

No fees are believed due for this submission. However, if a fee is due, the Commissioner is hereby authorized to charge payment of any fees associated with this communication, to Applicant's Deposit Account No. 010535. Additionally, the Commissioner is hereby authorized to charge payment or credit overpayment of any fees during the pendency of this application to Applicant's Deposit Account No. 010535.

Respectfully submitted,  
AMYLIN PHARMACEUTICALS, INC.

Dated: September 18, 2006

By: Karen Zachow  
Karen Zachow  
Registration No. 46,332

AMYLIN PHARMACEUTICALS, INC.  
9360 Town Centre Drive  
San Diego, CA 92121  
Telephone: 858.552.2200  
Facsimile: 858.552.1936



USSN 10/576,061  
Atty. Docket No. 0302-UTL2

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Appl. Serial No.:** 10/576,061

**Inventors:** Alain D. BARON, et al

**Filed:** April 17, 2006

**Title:** SILYL PHENOLS FOR PROMOTING  
VASCULAR HEALTH

**Confirmation No.:** 6693

**TC/A.U.:** Not Yet Assigned

**Examiner:** Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

In compliance with 37 C.F.R. §1.56, the patent documents listed on the attached Form PTO/SB/08A are being submitted herewith for consideration by the Examiner. In accordance with 37 C.F.R. 1.98, a copy of each of the listed items, other than U.S. Patents and U.S. Patent Application Publications, is included herewith. Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08A, indicating that the information has been considered and made of record herein.

The references are being cited only in the interests of candor and without any admission that they constitute statutory prior art or contain matter which anticipates the invention or which would render the same obvious, either singly or in combination, to a person of ordinary skill in the art.


---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8a OR  
FACSIMILE TRANSMISSION UNDER 37 C.F.R. 1.8**

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being facsimile transmitted to the USPTO at facsimile number (571) 273-8300, or deposited with the United States Postal Service on the date shown below with sufficient First Class postage in an envelope addressed to the Commissioner for Patents, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Date of Deposit

9/18/06

  
Signature of Person Mailing Paper  
Deborah Wykes  
Name of Person Mailing Paper

This Information Disclosure Statement is being submitted pursuant to 37 C.F.R. 1.97(b) in that Applicants believe that it is being filed before the mailing date of the first Office Action on the merits. Accordingly, neither a statement nor a fee under 37 C.F.R. 1.97(c) is required. If Applicants are mistaken, and the mailing date of the first Office Action on the merits precedes the filing of this Supplemental Information Disclosure Statement, Applicants authorize that the fee due under 37 C.F.R. 1.17(p) be charged to Deposit Account No 010535. Additionally, the Commissioner is hereby authorized to charge payment or credit overpayment of any fees during the pendency of this application to Applicant's Deposit Account No. 010535.


Respectfully Submitted

AMYLIN PHARMACEUTICALS, INC.

Dated: 18 September 2006

Karen R. Zachow  
Karen R. Zachow, Ph.D.  
Registration No. 46,332

AMYLIN PHARMACEUTICALS, INC.  
9373 Towne Centre Drive  
San Diego, CA 92121  
Telephone: (858) 552-2200  
Facsimile: (858) 552-1936



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1

of 5

**Complete if Known**

Application Number	10/576,061
Filing Date	April 17, 2006
First Named Inventor	Alain D. BARON, et al
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	0302-UTL2-0

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	001	US- 20030176413 A1	09-18-2003	ASBEROM, Theodros	
	002	US- 5,065,744	11-19-1991	ZUMANOWSHKY, Zinovy	
	003	US- 5,155,250	10-13-1992	PARKER, Roger A.	
	004	US- 5,532,400	07-02-1996	PARKER, Roger A.	
	005	US- 5,962,435	10-05-1999	MAO, Simon J. T.	
	006	US- 5,677,291	10-14-1997	MAO, Simon J. T.	
	007	US- 5,734,077	03-31-1998	REGNIER, Gilbert	
	008	US- 5,795,876	08-18-1998	WRIGHT, Paul S.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	009	EP 1151755	11-07-2001	SINGH, Amarjit		
	010	EP 1205180	05-15-2002	LACY, Jonathan Ernest		
	011	FR 2710535	04-07-1995	FARAH, Nabil		
	012	WO 92/10996	07-09-1992	BASSLER, Kenneth G.		
	013	WO 98/51289	11-19-1998	MEDFORD, Russell M.		
	014	WO 98/42327	10-01-1998	COTE, Gilles		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

0302-UTL2-0

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

**Complete if Known**

**(Use as many sheets as necessary)**

Sheet 3

of 5

Application Number	10/576,061
Filing Date	April 17, 2006
First Named Inventor	Alain D. BARON, et al
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	0302-UTL2-0

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	021	WO 05/37291	04-28-2005	BARON, Alain D.		

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/576,061
		Filing Date	April 17, 2006
		First Named Inventor	Alain D. BARON, et al
		Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
Sheet 4	of 5	Attorney Docket Number	0302-UTL2-0

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	022	ANGULO, et al, "Rationale for the Combination of PGE1 and S-Nitroso-glutathione to Induce Relaxation of Human Penile Smooth Muscle," J. Pharm Exp Ther (2000) 295:586-593	
	023	ANNUK, et al, "Oxidative Stress and Endothelial Function in Chronic Renal Failure," J Am Soc Nephrol (2001) 12:2747-2752.	
	024	BOLTON, et al, "Endothelial Dysfunction in Chronic Renal Failure: Roles of Lipoprotein Oxidation and Pro-Inflammatory Cytokines," Jephrol Dial Transplant. (2001) 16:1189-1197	
	025	CARMELIET, et al, "Vascular Wound Healing and Neointima Formation Induced by Perivascular Electric Injury in Mice," Am J Pathol (1997) 150:761-776.	
	026	DINSMORE, et al, "ABC of Sexual Health: Erectile Dysfunction," Brit. Med. J. (1999) 318:387-390.	
	027	FELDMAN, et al, "Impotence and Its Medical and Psychosocial Correlates: Results of the Massachusetts Male Aging Study," J. Urol. (1994) 151(1):54-61.	
	028	FISHMAN, et al, "Endothelial Regeneration in the Rat Carotid Artery and the Significance of Endothelial Denudation in the Pathogenesis...", Lab Invest (1975) 32:339-351	
	029	GRAUL, et al, "Latest Findings on the Diagnosis and Treatment of Erectile Dysfunction," Drug News & Perspect (1996) 9:572-575.	
	030	JOHANNES, et al, "Incidence of Erectile Dysfunction in Men 40 to 69 Years Old: Longitudinal Results From the Massachusetts Male Aging Study," J. Urol. (2000) 163:460-63.	
	031	KIKUCHI, Shinji, "Photochemically Induced Endothelial Injury in the Mouse as a Screening Model for Inhibitors...", Atheroscler Thromb Vasc Bio (1998) 18:1069-1078.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/576,061
		Filing Date	April 17, 2006
		First Named Inventor	Alain D. BARON, et al
		Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
Sheet 5	of 5	Attorney Docket Number	0302-UTL2-0

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	032	KUMAR, et al, "Remodeling with Neointima Formation in the Mouse Carotid Artery After Cessation of Blood Flow," Arterioscler Thromb Vasc Biol (1997) 17:2238-2244.	
	033	LINDNER, et al, "Mouse Model of Arterial Injury," Circ Res (1993) 73:792-796.	
	034	MORELAND, et al, "Sildenafil, A Novel Inhibitor of Phosphodiesterase Type 5 in Human Corpus Cavernosum Smooth Muscle Cells," Life Sci (1998) 62:309-318.	
	035	MOROI, et al "Interaction of Genetic Deficiency of Endothelial Nitric Oxide, Gender, and Pregnancy in Vascular Response to Injury in Mice," J Clin Invest (1998) 101:1225-1232	
	036	ROY-CHAUDHURY, et al, "Venous Neointimal Hyperplasia in Polytetrafluoroethylene Dialysis Grafts," Kidney Int (2001) 59:2325-2334.	
	037	SCHMIDT, R.J., "Total Nitric Oxide Production is low in Patients with Chronic Renal Disease," Kidney Int (2000) 58:1261-1266.	
	038	SLOW, Richard C.M., "Heme Oxygenase-carbon Monoxide Signalling Pathway in Atherosclerosis: Anti-atherogenic Actions of Bilirubin...?" Cardiovasc Res (1999) 41:385-394	
	039	TERRETT, Nicholas K., "Sildenafil (VIAGRA), a Potent and Selective Inhibitor of Type 5 CGMP Phosphodiesterase With Utility..., " Bioorg Med Chem Lett (1996) 6:1819-1824	
	040	YORAM, Vardi, "Oral Pharmacotherapy in Erectile Dysfunction," Cur Opin in Urology (1997) 7:349-353	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.